相似文献
1
The Role of Calcium/Calmodulin-Dependent Protein Kinase II Activation in Hypertrophic Cardiomyopathy.
Circulation. 2016 Nov 29;134(22):1749-1751. doi: 10.1161/CIRCULATIONAHA.116.025455.
2
Pathogenesis of Hypertrophic Cardiomyopathy is Mutation Rather Than Disease Specific: A Comparison of the Cardiac Troponin T E163R and R92Q Mouse Models.
J Am Heart Assoc. 2017 Jul 22;6(7):e005407. doi: 10.1161/JAHA.116.005407.
3
Calcium/calmodulin-dependent protein kinase II couples Wnt signaling with histone deacetylase 4 and mediates dishevelled-induced cardiomyopathy.
Hypertension. 2015 Feb;65(2):335-44. doi: 10.1161/HYPERTENSIONAHA.114.04467. Epub 2014 Dec 8.
4
CaMKII-mediated phosphorylation of RyR2 plays a crucial role in aberrant Ca release as an arrhythmogenic substrate in cardiac troponin T-related familial hypertrophic cardiomyopathy.
Biochem Biophys Res Commun. 2018 Feb 19;496(4):1250-1256. doi: 10.1016/j.bbrc.2018.01.181. Epub 2018 Jan 31.
5
Transcriptional upregulation of calcineurin Abeta by endothelin-1 is partially mediated by calcium/calmodulin-dependent protein kinase IIdelta3 in rat cardiomyocytes.
Biochim Biophys Acta. 2010 May-Jun;1799(5-6):429-41. doi: 10.1016/j.bbagrm.2010.02.004. Epub 2010 Mar 6.
6
Calcium/calmodulin-dependent kinase II and nitric oxide synthase 1-dependent modulation of ryanodine receptors during β-adrenergic stimulation is restricted to the dyadic cleft.
J Physiol. 2016 Oct 15;594(20):5923-5939. doi: 10.1113/JP271965. Epub 2016 Jul 3.
7
Calcium/Calmodulin Protein Kinase II-Dependent Ryanodine Receptor Phosphorylation Mediates Cardiac Contractile Dysfunction Associated With Sepsis.
Crit Care Med. 2017 Apr;45(4):e399-e408. doi: 10.1097/CCM.0000000000002101.
8
Relevance of calmodulin/CaMKII activation for arrhythmogenesis in the AV block dog.
Heart Rhythm. 2012 Nov;9(11):1875-83. doi: 10.1016/j.hrthm.2012.07.023. Epub 2012 Jul 27.
9
Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance.
J Physiol. 2017 Jun 15;595(12):4089-4108. doi: 10.1113/JP273714. Epub 2017 Mar 2.
10
Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.
Mol Pharmacol. 1996 Sep;50(3):549-55.
引用本文的文献
1
Hyperpolarized-MRI in Hypertrophic Cardiomyopathy: A Narrative Review.
Clin Med Insights Cardiol. 2025 Aug 29;19:11795468251369234. doi: 10.1177/11795468251369234. eCollection 2025.
2
Measurement of Myofilament-Localized Calcium Dynamics in Adult Cardiomyocytes and the Effect of Hypertrophic Cardiomyopathy Mutations.
Circ Res. 2019 Apr 12;124(8):1228-1239. doi: 10.1161/CIRCRESAHA.118.314600.
3
Morphomechanic phenotypic variability of sarcomeric cardiomyopathies: A multifactorial polygenic perspective.
J Mol Cell Cardiol. 2019 Jan;126:23-35. doi: 10.1016/j.yjmcc.2018.10.024. Epub 2018 Nov 10.
4
Hypertrophic cardiomyopathy mutations increase myofilament Ca buffering, alter intracellular Ca handling, and stimulate Ca-dependent signaling.
J Biol Chem. 2018 Jul 6;293(27):10487-10499. doi: 10.1074/jbc.RA118.002081. Epub 2018 May 14.
5
An ImmunoSignature test distinguishes Trypanosoma cruzi, hepatitis B, hepatitis C and West Nile virus seropositivity among asymptomatic blood donors.
PLoS Negl Trop Dis. 2017 Sep 5;11(9):e0005882. doi: 10.1371/journal.pntd.0005882. eCollection 2017 Sep.
本文引用的文献
1
Evolution of hypertrophic cardiomyopathy in sarcomere mutation carriers.
Heart. 2016 Nov 15;102(22):1805-1812. doi: 10.1136/heartjnl-2016-310015. Epub 2016 Sep 2.
2
Atomic resolution probe for allostery in the regulatory thin filament.
Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3257-62. doi: 10.1073/pnas.1519541113. Epub 2016 Mar 8.
3
Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.
JACC Heart Fail. 2015 Feb;3(2):180-8. doi: 10.1016/j.jchf.2014.08.003. Epub 2014 Oct 31.
4
Mechanochemotransduction during cardiomyocyte contraction is mediated by localized nitric oxide signaling.
Sci Signal. 2014 Mar 18;7(317):ra27. doi: 10.1126/scisignal.2005046.
5
Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
J Mol Cell Cardiol. 2013 Oct;63:189-98. doi: 10.1016/j.yjmcc.2013.07.011. Epub 2013 Jul 26.
6
A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations.
Heart. 2013 Dec;99(24):1800-11. doi: 10.1136/heartjnl-2013-303939. Epub 2013 May 14.
7
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.
Circulation. 2013 Feb 5;127(5):575-84. doi: 10.1161/CIRCULATIONAHA.112.134932. Epub 2012 Dec 27.
8
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
J Am Coll Cardiol. 2011 Dec 13;58(25):e212-60. doi: 10.1016/j.jacc.2011.06.011. Epub 2011 Nov 8.
9
Ca²⁺-calmodulin-dependent protein kinase II regulation of cardiac excitation-transcription coupling.
Heart Rhythm. 2011 Jul;8(7):1101-4. doi: 10.1016/j.hrthm.2011.01.030. Epub 2011 Jan 18.
10
Temporal and mutation-specific alterations in Ca2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models.
Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H614-26. doi: 10.1152/ajpheart.01143.2008. Epub 2009 Jun 5.
Zotero 插件